Connection | Profiles RNS

Login to edit your profile (add a photo, awards, links to other websites, etc.)

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

AJANI, JAFFER A

One or more keywords matched the following items that are connected to AJANI, JAFFER A

Item Type	Name
Academic Article	Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing.
Academic Article	Modern oncological approaches to gastric adenocarcinoma.
Academic Article	Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer
Academic Article	Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.
Academic Article	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy.
Academic Article	Advanced gastric adenocarcinoma: optimizing therapy options.
Academic Article	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Academic Article	Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Concept	Trastuzumab
Academic Article	Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Academic Article	HERIZON-GEA-01: Zanidatamab + chemo?? tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Academic Article	Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
Academic Article	Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

Search Criteria

Trastuzumab